Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGIC-8: Nivolumab +/- BMS-986253 + Degarelix in Hormone-Sensitive Prostate Cancer
NCT03689699Phase 2Completed
- Start
- Oct 2018
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, adakitug in prostate cancer (PCa). Started Oct 2018; status: completed.
02
Drugs
nivolumabadakitug
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03689699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03689699.